Business Wire

MA-EVERBRIDGE

25.1.2021 13:32:08 CET | Business Wire | Press release

Share
Everbridge Awarded Statewide Vaccine Distribution Deployment Across West Virginia; Everbridge Software Enables Governments, Hospitals and Businesses to Coordinate Rapid Delivery and Communications of COVID-19 Vaccine

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced COVID-19 Shield™: Vaccine Distribution , an extension to its CEM platform offering risk insights, logistics awareness and vaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia , and the County of Sarasota, Florida , among others.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005258/en/

“We have partnered with Everbridge,” said Governor Jim Justice of West Virginia in a recent press conference for state residents. “Everbridge helps states notify their citizens when there’s a fire, a flood, or a hurricane, but now they are going to help us coordinate vaccines as we can get them from the federal government. We will be the first state to turn on this new vaccine scheduling system. Everbridge helped us stand this up in one week’s time.”

In the U.S., healthcare experts have stated : “at a pace of one million doses a day, the virus wouldn’t be contained until sometime in 2022.” A recent survey also reveals that 6 in 10 Americans do not know when or where to get the vaccine. In addition, the logistics of moving this type of vaccine across the country in a short period of time creates a substantial challenge , especially given the cruciality of cold chain monitoring .

Added Gov. Justice, “This system [provides residents] the ability to put your information in directly and helps us coordinate when vaccines are available to notify you when and where to come to get your vaccine. You will get a message back after you’ve registered to confirm that you are in the system and we will send you updates regularly. The system sends emails, texts, and phone calls. Whatever way you want us to notify you about your availability, [Everbridge] will let you pick up on just that.”

“During a pandemic, efficient, expeditious and equitable distribution and administration of [the] approved vaccine is critical,” as stated by the U.S. Centers for Disease Control and Prevention (CDC) in their recent guidelines . Everbridge’s new COVID-19 Shield™: Vaccine Distribution software offers federal, state and local governments as well as businesses and healthcare systems new capabilities to: better manage vaccine supply chains amidst other concurrent critical events, analyze risk of virus spread, avoid operational disruptions, and ensure the smooth rollout of vaccines to employees and citizens with easy-to-deploy software integrations.

For governments, Everbridge enables state, city and county leaders to rapidly coordinate communication across the population, automate appointment signup and monitor registrations, track vaccine availability, ensure doses are shipped to proper facilities to avoid spoilage, and enable citizen scheduling to avoid long waits and call center challenges.

Demonstrating the extreme pent up demand and need for technology to assist in the communications, scheduling and distribution of the vaccine, the County of Sarasota, Florida leveraged Everbridge’s vaccine distribution software to enable 50,000 residents to sign up for the COVID-19 vaccine in the first hour of launch, which has been reported as ‘a giant leap forward.’ “We are utilizing Everbridge to coordinate the vaccine distribution in our community,” said Rich Collins, Director of Sarasota County Emergency Services. “The system aids in tracking and prioritizing this process, which allows us to serve our vulnerable populations and frontline workers.”

“We applaud Governor Justice and the state of West Virginia for their leadership in applying best practices to help keep their citizens safer and accurately informed through effective vaccine distribution. Solving this public health crisis faster will unlock the ability for governments to fully re-open economies for the betterment of all states, people and businesses,” said David Meredith, CEO of Everbridge. “The expansion of the Everbridge critical event management software platform to include vaccine distribution creates new ways for government, healthcare and all types of businesses to automate logistics, maintain vital communications and keep people safe during this crucial rollout.”

With Everbridge’s COVID-19 Shield™: Vaccine Distribution, enterprise customers gain capabilities to: coordinate the number of employees who have been vaccinated, manage population density and access to office buildings based on vaccination status, and receive timely alerts when employees report signs of illness so they can quickly respond to safeguard staff and visitors.

“Garnet Healthcare is providing mobile COVID testing and care across Vermont, New York, and Massachusetts,” said Ryan Ferris, CEO & Co-founder at Garnet Healthcare , which provides patient logistics, care coordination, and clinical diagnostics to healthcare institutions, corporate clients, and governmental agencies across New England. “Everbridge’s CEM Platform provides situational awareness of threats to our clinical logistics which could inhibit or delay these critical services. In addition, the platform provides coordination support to help us manage the testing process and follow-up with patients supporting our end-to-end clinical services.”

The new Everbridge COVID-19 Shield™: Vaccine Distribution software solution includes the following features among the suite’s broader CEM capabilities:

  • Enhanced COVID-19 Risk Feed showcasing vital real-time information, including the incidence of new virus strains and vaccine related intelligence;
  • Crisis Management Module to follow, log and audit the transport, handling, and/or administration of the vaccine;
  • Vaccine Distribution Logistics Service to provide situational awareness to better manage vaccine supply chains;
  • Customized Employee Surveys to help confirm whether employees have received the vaccine;
  • Appointment Management Tool to help manage the scheduling, tracking and communications of vaccine administration; and
  • Out-of-Box Workflows in Smart Orchestration to help improve distribution management, such as vaccine appointment follow-ups.

“Everbridge helps to bridge the gap between the public sector and the private sector,” said Mark Aprigliano, Senior Director, Public Safety at Jackson Health System . “Their CEM Platform provides situational awareness of threats to the supply chain for the vaccine which could inhibit or delay distribution. It also provides a common operating picture to all of the stakeholders in that supply chain, providing visibility and a coordinated effort from manufacturing to point of vaccination.”

To learn more best practices for distribution and management of the vaccine rollout, join Everbridge and Dr. Scott Gottlieb, former U.S. Food & Drug Administration Commissioner for a discussion entitled “The End of the Pandemic: Successful Vaccine Distribution ” on Wednesday, January 27, 2021 at 11:30 a.m. ET.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,400 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release

All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye